Regeneron的新Eylea HD显示,有望在不危及视力的情况下减少对肌肉水肿病人的注射。 Regeneron's new Eylea HD shows promise in reducing injections for macular edema patients without compromising vision.

Regenenron制药公司报告说,Eylea HD第3阶段的结果是积极的,表明每8周服用静脉闭塞后,它能够保持雄性水肿患者的视觉敏锐度,而Eylea每4周服用一次标准剂量。 Regeneron Pharmaceuticals reported positive Phase 3 results for Eylea HD, showing it can maintain visual acuity in patients with macular edema following retinal vein occlusion when dosed every 8 weeks, compared to standard Eylea dosed every 4 weeks. Eylea HD具有类似的安全特征,有可能将所需注射的数量减半。 Eylea HD has a similar safety profile and could potentially halve the number of injections needed. 雷格纳龙计划在2025年第一季度向FDA提交这些发现. Regeneron plans to submit the findings to the FDA in the first quarter of 2025.